Notably, CD133-targeted CAR-T cells have produced stable disease or partial response in subgroups of patients with pancreatic cancer, whereas CLDN18.2-directed CAR-T cells have shown good disease control rates in gastric, pancreatic, and gastro-esophageal malignancies. This evidence concerns the gene PROM1 and familial pancreatic carcinoma.